LI
RYTM icon

Leap Investments’s Rhythm Pharmaceuticals RYTM Stock Holding History

Leap Investments’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,800
Closed -$255K – 555
2019
Q3 		$255K Buy
+11,800
New +$253K 0.13% 262

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Leap Investments's RYTM Position: Q4 2019 in Review

Leap Investments sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2019, closing a stake of 11,800 shares — an estimated $255K sold.

Leap Investments first reported a position in RYTM in Q3 2019 and held it in 1 quarter. The position peaked at $255K in Q3 2019. 89 funds tracked by Wall St. Rank hold RYTM as of Q4 2019.

  • Leap Investments reported no remaining Rhythm Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Leap Investments sold 11,800 Rhythm Pharmaceuticals shares in Q4 2019, an estimated $255K.
  • Leap Investments first reported a position in Rhythm Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Leap Investments's Rhythm Pharmaceuticals position peaked at $255K in Q3 2019.
  • 89 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.